201 related articles for article (PubMed ID: 30065373)
1. Surprising CRISPR roadblocks.
Rusk N
Nat Methods; 2018 Aug; 15(8):569. PubMed ID: 30065373
[No Abstract] [Full Text] [Related]
2. Restoring the p53 'Guardian' Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9.
Chira S; Gulei D; Hajitou A; Berindan-Neagoe I
Trends Biotechnol; 2018 Jul; 36(7):653-660. PubMed ID: 29478674
[TBL] [Abstract][Full Text] [Related]
3. Counterpoint: The Potential Harms of Human Gene Editing Using CRISPR-Cas9.
Baylis F
Clin Chem; 2018 Mar; 64(3):489-491. PubMed ID: 29490999
[No Abstract] [Full Text] [Related]
4. p53 activation: a checkpoint for precision genome editing?
Conti A; Di Micco R
Genome Med; 2018 Aug; 10(1):66. PubMed ID: 30119695
[TBL] [Abstract][Full Text] [Related]
5. Gene editing using CRISPR-Cas9 for the treatment of lung cancer.
Castillo A
Colomb Med (Cali); 2016 Dec; 47(4):178-180. PubMed ID: 28293040
[No Abstract] [Full Text] [Related]
6. [CRISPR-Cas system as molecular scissors for gene therapy].
Heinz GA; Mashreghi MF
Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
[TBL] [Abstract][Full Text] [Related]
7. [The CRISPR-Cas system: beyond genome editing].
Croteau FR; Rousseau GM; Moineau S
Med Sci (Paris); 2018 Oct; 34(10):813-819. PubMed ID: 30451675
[TBL] [Abstract][Full Text] [Related]
8. Ji Luo Elucidates the CRISPR Gene Editing Technology, and How It May Affect Cancer Therapy in the Future.
Luo J
Oncology (Williston Park); 2016 Oct; 30(10):879. PubMed ID: 27753053
[No Abstract] [Full Text] [Related]
9. Editor's comment on "CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein".
Hohmann S
Mol Genet Genomics; 2017 Jun; 292(3):535-536. PubMed ID: 28251316
[No Abstract] [Full Text] [Related]
10. CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy.
Zhang X; Wang L; Liu M; Li D
Sci China Life Sci; 2017 May; 60(5):468-475. PubMed ID: 28534255
[TBL] [Abstract][Full Text] [Related]
11. Application of the gene editing tool, CRISPR-Cas9, for treating neurodegenerative diseases.
Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
Neurochem Int; 2018 Jan; 112():187-196. PubMed ID: 28732771
[TBL] [Abstract][Full Text] [Related]
12. CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia.
Chadwick AC; Musunuru K
Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):12-18. PubMed ID: 28838920
[TBL] [Abstract][Full Text] [Related]
13. New Gene-Editing Tool Slowly Advances Into the Clinic.
Jenks S
J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 29117363
[No Abstract] [Full Text] [Related]
14. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
[TBL] [Abstract][Full Text] [Related]
15. The tsunami named CRISPR/Cas9.
Chneiweiss H
Rev Neurol (Paris); 2018; 174(7-8):487-488. PubMed ID: 29779853
[No Abstract] [Full Text] [Related]
16. CRISPR/Cas9 and p53: An Odd Couple Requiring Relationship Management.
Ylä-Herttuala S
Mol Ther; 2018 Dec; 26(12):2711. PubMed ID: 30454954
[No Abstract] [Full Text] [Related]
17. CRISPR Gene Editing Successfully Treats Lethal Monogenic Lung Disease in Utero.
Am J Med Genet A; 2019 Jul; 179(7):1116. PubMed ID: 31180191
[No Abstract] [Full Text] [Related]
18. Point: Treating Human Genetic Disease One Base Pair at a Time: The Benefits of Gene Editing.
Katsanis N
Clin Chem; 2018 Mar; 64(3):486-488. PubMed ID: 29490998
[No Abstract] [Full Text] [Related]
19. Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy.
Wong TWY; Cohn RD
Curr Gene Ther; 2017; 17(4):301-308. PubMed ID: 29173172
[TBL] [Abstract][Full Text] [Related]
20. Base Editing: Efficient Installation of Point Mutations with Minimal Byproducts.
Newby GA
Stem Cells Dev; 2019 Jun; 28(11):712-713. PubMed ID: 31107171
[No Abstract] [Full Text] [Related]
[Next] [New Search]
